BubbleGumbo
2021-11-11
[Miser]
[Miser]
Organon narrows 2021 guidance; agrees to acquire Forendo Pharma for $954M
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":870528325,"tweetId":"870528325","gmtCreate":1636636326821,"gmtModify":1636636327178,"author":{"id":3582966792980858,"idStr":"3582966792980858","authorId":3582966792980858,"authorIdStr":"3582966792980858","name":"BubbleGumbo","avatar":"https://static.tigerbbs.com/3ea67ad05fa0074d870d9c061d20bf79","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":17,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Miser] </span><span>[Miser] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Miser] </span><span>[Miser] </span><br></p></body></html>","text":"[Miser] [Miser]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/870528325","repostId":1144726166,"repostType":4,"repost":{"id":"1144726166","kind":"news","pubTimestamp":1636633893,"share":"https://www.laohu8.com/m/news/1144726166?lang=&edition=full","pubTime":"2021-11-11 20:31","market":"us","language":"en","title":"Organon narrows 2021 guidance; agrees to acquire Forendo Pharma for $954M","url":"https://stock-news.laohu8.com/highlight/detail?id=1144726166","media":"seekingalpha","summary":"Organon(NYSE:OGN)is trading flat in the pre-market after the company reported Q3 2021 financials exc","content":"<ul>\n <li>Organon(NYSE:OGN)is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed its full-year guidance.</li>\n <li>For the quarter, the topline dipped ~1% YoY to $1.6B after ~5% YoY growth recorded in the previous quarter.</li>\n <li>The contraction was led by established brands which brought ~$1.0B in sales posting a ~6% YoY decline. Meanwhile, women’s health and biosimilars recorded $381M and $140M in sales with a ~10% YoY decline and ~41% YoY growth, respectively.</li>\n <li>Revenue from the U.S. dropped ~7% YoY to $346M. China and Europe/ Canada brought $252M and $410M sales, posting ~12% YoY growth and ~4% YoY decline, respectively.</li>\n <li>Meanwhile, the gross margin narrowed to ~62% from ~63% in the previous quarter and ~67% in Q3 2020.</li>\n <li>The net income contracted ~41% YoY to $323M as SG&A expenses climbed ~21% YoY to $388M.</li>\n <li>For 2021, Organon (OGN) has revised its guidance for revenue and adjusted EBITDA margin to $6.2B - 6.3B and 36.5%-37.5% from $6.1B-$6.4B and 36%-38% estimated three months ago, respectively.</li>\n <li>Separately, the company announced an agreement to acquire Forendo Pharma, a clinical-stage pharma company focused on women’s health, for a total consideration of $954M. The transaction is expected to close in December 2021.</li>\n <li>Since its trading began in mid-May, Organon (OGN) has outperformed the broader market with over 10% gain YTD, as shown in the graph below.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/da5fa00825a970dc6e6432f20d5671f9\" tg-width=\"1571\" tg-height=\"542\" width=\"100%\" height=\"auto\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organon narrows 2021 guidance; agrees to acquire Forendo Pharma for $954M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganon narrows 2021 guidance; agrees to acquire Forendo Pharma for $954M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-11 20:31 GMT+8 <a href=https://seekingalpha.com/news/3769385-organon-narrows-2021-guidance-agrees-to-acquire-forendo-pharma-for-954m><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Organon(NYSE:OGN)is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3769385-organon-narrows-2021-guidance-agrees-to-acquire-forendo-pharma-for-954m\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OGN":"Organon & Co"},"source_url":"https://seekingalpha.com/news/3769385-organon-narrows-2021-guidance-agrees-to-acquire-forendo-pharma-for-954m","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1144726166","content_text":"Organon(NYSE:OGN)is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed its full-year guidance.\nFor the quarter, the topline dipped ~1% YoY to $1.6B after ~5% YoY growth recorded in the previous quarter.\nThe contraction was led by established brands which brought ~$1.0B in sales posting a ~6% YoY decline. Meanwhile, women’s health and biosimilars recorded $381M and $140M in sales with a ~10% YoY decline and ~41% YoY growth, respectively.\nRevenue from the U.S. dropped ~7% YoY to $346M. China and Europe/ Canada brought $252M and $410M sales, posting ~12% YoY growth and ~4% YoY decline, respectively.\nMeanwhile, the gross margin narrowed to ~62% from ~63% in the previous quarter and ~67% in Q3 2020.\nThe net income contracted ~41% YoY to $323M as SG&A expenses climbed ~21% YoY to $388M.\nFor 2021, Organon (OGN) has revised its guidance for revenue and adjusted EBITDA margin to $6.2B - 6.3B and 36.5%-37.5% from $6.1B-$6.4B and 36%-38% estimated three months ago, respectively.\nSeparately, the company announced an agreement to acquire Forendo Pharma, a clinical-stage pharma company focused on women’s health, for a total consideration of $954M. The transaction is expected to close in December 2021.\nSince its trading began in mid-May, Organon (OGN) has outperformed the broader market with over 10% gain YTD, as shown in the graph below.","news_type":1},"isVote":1,"tweetType":1,"viewCount":796,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/870528325"}
精彩评论